Abstract
Polymorphisms in carcinogen- and drug-metabolizing enzymes may increase the risk of acute myeloid leukemia (AML) and may influence prognosis. We report that the polymorphic variant of the cytochrome P450 CYP1A1*2A, present in 11.3% of patients, is an independent unfavorable prognostic factor for failure-free and overall survival in patients with AML.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Alleles*
-
Cytochrome P-450 CYP1A1 / genetics*
-
Cytogenetics
-
Disease-Free Survival
-
Genetic Predisposition to Disease*
-
Leukemia, Myeloid, Acute / genetics*
-
Leukemia, Myeloid, Acute / mortality
-
Polymorphism, Genetic
-
Prognosis
-
Remission Induction
-
Risk
-
Treatment Outcome